{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:04Z","timestamp":1767135064242,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd011316","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T00:00:00Z","timestamp":1432166400000}}],"reference-count":88,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011316.pub2","type":"journal-article","created":{"date-parts":[[2015,5,21]],"date-time":"2015-05-21T12:57:06Z","timestamp":1432213026000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids"],"prefix":"10.1002","volume":"2017","author":[{"given":"Kayleigh M","family":"Kew","sequence":"first","affiliation":[{"name":"BMJ Knowledge Centre; British Medical Journal Technology Assessment Group (BMJ-TAG); BMA House Tavistock Square London UK WC1H 9JR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Beggs","sequence":"additional","affiliation":[{"name":"Royal Hobart Hospital; Department of Paediatrics; 48 Liverpool Street Hobart Tasmania Australia 7000"},{"name":"University of Tasmania; School of Medicine; Hobart Tasmania Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaleen","family":"Ahmad","sequence":"additional","affiliation":[{"name":"St George's, University of London; Population Health Research Institute; London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,21]]},"reference":[{"key":"10.1002\/14651858.CD011316.pub2-BIB0001|cit1","first-page":"A431","article-title":"Adjustable dosing with budesonide\/formoterol achieves sustained guideline 'well-controlled asthma' following step down in treatment [Abstract]","volume":"26","author":"Aalbers","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0002|cit2","unstructured":"AstraZeneca A 12-week randomized, double-blind, double-dummy, placebo- and active-controlled study of Symbicort pMDI administered once daily in adults and adolescents with asthma http:\/\/www.astrazenecaclinicaltrials.com\/"},{"issue":"1","key":"10.1002\/14651858.CD011316.pub2-BIB0003|cit3","first-page":"49","article-title":"Efficacy and safety of budesonide\/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once- and twice-daily dosing in patients with asthma","volume":"31","author":"Berger","year":"2010","journal-title":"Allergy and Asthma Proceedings"},{"issue":"(Suppl 4)","key":"10.1002\/14651858.CD011316.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"A83","DOI":"10.1136\/thx.2010.150961.16","article-title":"P16 Fluticasone propionate\/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently: A randomised controlled trial [Abstract]","volume":"65","author":"Bumbacea","year":"2010","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD011316.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.clinthera.2007.07.021","article-title":"Tolerability of a salmeterol xinafoate\/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study","volume":"29","author":"Cowie","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD011316.pub2-BIB0007|cit6","first-page":"20","article-title":"Erratum: Adjustable maintenance dosing with budesonide\/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five month multicentre Canadian study [Canadian Respiratory Journal (2003) vol. 10 (8) (427-434)]","volume":"11","author":"FitzGerald","year":"2004","journal-title":"Canadian Respiratory Journal [Revue canadienne de pneumologie]"},{"issue":"8","key":"10.1002\/14651858.CD011316.pub2-BIB0006|cit7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1155\/2003\/298039","article-title":"Adjustable maintenance dosing with budesonide\/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five-month multicentre Canadian study","volume":"10","author":"FitzGerald","year":"2003","journal-title":"Canadian Respiratory Journal [Revue canadienne de pneumologie]"},{"issue":"6","key":"10.1002\/14651858.CD011316.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1067\/mai.2002.123869","article-title":"Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone","volume":"109","author":"Fowler","year":"2002","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0009|cit9","unstructured":"GlaxoSmithKline Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long-acting inhaled 2-agonist http:\/\/www.gsk-clinicalstudyregister.com\/"},{"issue":"3","key":"10.1002\/14651858.CD011316.pub2-BIB0010|cit10","first-page":"A213","article-title":"Comparison of different treatment strategies in stepping down combination treatment withdrawing the LABA versus reducing the ICS dose [Abstract]","volume":"3","author":"Godard","year":"2006","journal-title":"Proceedings of the American Thoracic Society"},{"issue":"8","key":"10.1002\/14651858.CD011316.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.rmed.2008.03.014","article-title":"Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study","volume":"102","author":"Godard","year":"2008","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0012|cit12","unstructured":"GSK ADA109315 A retrospective study of healthcare utilization and costs of step-down therapy in asthma patients receiving fluticasone propionate\/salmeterol combination www.gsk-clinicalstudyregister.com\/files2\/26012.pdf"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0013|cit13","unstructured":"GlaxoSmithKline Randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate\/salmeterol Diskus combination product 100\/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10 mg Q www.gsk-clinicalstudyregister.com\/"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0014|cit14","unstructured":"Oppenheimer J Stauffer J Waitkus-Edwards K Yancey S Prillaman B Sutton L \u201cStepping down\u201d from fluticasone propionate\/salmeterol 100\/50mcg Diskus results in loss of asthma control American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando 2004 J94"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0015|cit15","unstructured":"GSK SMS30046 Effects of long-term administration of salmeterol on clinical symptoms, inhaled corticosteroid requirement and bronchial reactivity, and the effect of stopping long-term salmeterol treatment www.gsk-clinicalstudyregister.com\/study\/SMS30046#rs"},{"issue":"7092","key":"10.1002\/14651858.CD011316.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/bmj.314.7092.1441","article-title":"Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study","volume":"314","author":"Wilding","year":"1997","journal-title":"BMJ"},{"issue":"Suppl 25","key":"10.1002\/14651858.CD011316.pub2-BIB0017|cit17","first-page":"3S","article-title":"A controlled trial of beta2-agonist dose reduction in asthmatic patients on high doses of beta2-agonist [Abstract]","volume":"10","author":"Harrison","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD011316.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.rmed.2003.07.010","article-title":"Adjustable and fixed dosing with budesonide\/formoterol via a single inhaler in asthma patients: the ASSURE study","volume":"98","author":"Ind","year":"2004","journal-title":"Respiratory Medicine"},{"issue":"(suppl 48)","key":"10.1002\/14651858.CD011316.pub2-BIB0019|cit19","first-page":"309s","article-title":"Stepping down from fluticasone propionate\/salmeterol 100\/50mcg Diskus results in loss of asthma control [Abstract]","volume":"24","author":"Dorinsky","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"(4 Suppl)","key":"10.1002\/14651858.CD011316.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"758S","DOI":"10.1378\/chest.126.4_MeetingAbstracts.758S-a","article-title":"\"Stepping down\" from fluticasone propionate\/salmeterol 100\/50mcg Diskus(R) results in loss of asthma control: lack of effect of ethnic origin [Abstract]","volume":"126","author":"Dorinsky","year":"2004","journal-title":"Chest"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0021|cit21","unstructured":"GlaxoSmithKline A multicenter, randomized, double-blind, double-dummy, parallel group, 16-week comparison of asthma control in adolescents and adults receiving either fluticasone propionate\/salmeterol Diskus combination product 100\/50 mcg BID, fluticasone propionate Diskus 100 mcg BID, salmeterol xinafoate Diskus 50 mcg BID, or oral montelukast 10mg QD www.gsk-clinicalstudyregister.com\/"},{"issue":"2","key":"10.1002\/14651858.CD011316.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.jaci.2003.12.325","article-title":"Loss of asthma control when patients receiving fluticasone propionate\/salmeterol 100\/50\u03bcg Diskus are \u201cstepped down\u201d to fluticasone propionate, salmeterol or montelukast alone","volume":"113","author":"Koenig","year":"2004","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"8","key":"10.1002\/14651858.CD011316.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/02770900802168695","article-title":"Deterioration in asthma control when subjects receiving fluticasone propionate\/salmeterol 100\/50 mcg Diskus are 'stepped-down'","volume":"45","author":"Koenig","year":"2008","journal-title":"Journal of Asthma"},{"issue":"7","key":"10.1002\/14651858.CD011316.pub2-BIB0024|cit24","first-page":"498","article-title":"A clinical study on the significance of airway hyperresponsiveness monitoring in the adjustment of combined therapy for asthmatic patients","volume":"30","author":"Liu","year":"2007","journal-title":"Zhonghua jie he he hu xi za zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]"},{"issue":"4","key":"10.1002\/14651858.CD011316.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.136.4_MeetingAbstracts.8S","article-title":"Safety and tolerability of medium-dose mometasone furoate\/formoterol treatment versus mometasone furoate or formoterol monotherapies in persistent asthmatics who previously used medium-dose inhaled corticosteroids (alone or with long-acting beta2-agonist) [Abstract]","volume":"136","author":"Nathan","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD011316.pub2-BIB0026|cit26","first-page":"A58","article-title":"Safety and tolerability of mometasone furoate\/formoterol for persistent asthma subjects who previously were treated with medium-dose inhaled corticosteroids (alone or with a long-acting beta2-agonist) [Abstract]","volume":"103","author":"Nathan","year":"2009","journal-title":"Annals of Allergy, Asthma & Immunology"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0027|cit27","unstructured":"NCT00158834 Pediatric asthma study using stepwise treatment with two Food and Drug Administration approved asthma medications www.clinicaltrials.gov\/ct2\/show\/study\/NCT00158834"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0028|cit28","unstructured":"NCT01565031 Prediction of future risk in patients with controlled asthma https:\/\/clinicaltrials.gov\/show\/NCT01565031"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0029|cit29","unstructured":"NCT02094937 A study to compare the efficacy and safety of fluticasone furoate (FF) 100 mcg once daily with fluticasone propionate (FP) 250 mcg twice daily (BD) and FP 100 mcg BD in well-controlled asthmatic Japanese subjects https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02094937"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0030|cit30","unstructured":"Kersten E The effect of stepping down asthma therapy in clinically stable children on exercise induced asthma www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=2045"},{"issue":"7","key":"10.1002\/14651858.CD011316.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3109\/02770903.2013.795588","article-title":"Step-down of budesonide\/formoterol in early stages of asthma treatment leads to insufficient anti-inflammatory effect","volume":"50","author":"Obase","year":"2013","journal-title":"Journal of Asthma"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD011316.pub2-BIB0032|cit32","first-page":"A1278","article-title":"Six months step down treatment from high dose ICS\/LABA combination therapy in asthma [Abstract]","volume":"183","author":"Paggiaro","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"suppl 55","key":"10.1002\/14651858.CD011316.pub2-BIB0033|cit33","first-page":"722s [P3967]","article-title":"Asthma control and lung function after step down from high dose ICS\/LABA combination therapy [Abstract]","volume":"38","author":"Paggiaro","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0034|cit34","unstructured":"NCT00497237 Prospective, randomised, open-label, multicentre, active drug controlled, parallel group design clinical trial of the efficacy and safety of beclomethasone dipropionate 400 Mcg + formoterol 24 mcg pMDI via HFA-134a (Foster\u2122) vs. fluticasone propionate 500 mcg + salmeterol xinafoate 100 mcg DPI (Seretide Diskus\u00ae) in the 6 months stepdown treatment of adult patients with controlled asthma https:\/\/clinicaltrials.gov\/show\/NCT00497237"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1465-9921-13-54","article-title":"Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial","volume":"13","author":"Papi","year":"2012","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0036|cit36","unstructured":"GlaxoSmithKline A 13-month, randomised, double-blind, parallel-group comparison of the efficacy of Seretide (fluticasone propionate\/salmeterol combination Accuhaler) and Flixotide (fluticasone propionate Accuhaler) when down-titrating the inhaled corticosteroid dose in asthmatic adults who have previously received Seretide 500\/50 mcg twice daily for at least 4wk www.gsk-clinicalstudyregister.com\/"},{"issue":"8","key":"10.1002\/14651858.CD011316.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.rmed.2010.04.003","article-title":"Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta(2)-agonist","volume":"104","author":"Reddel","year":"2010","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0038|cit38","unstructured":"Reddel HK Peyters MJ Wark PA Sand IB Jenkins CR Comparison of the efficacy of Seretide and Flixotide when down-titrating the inhaled corticosteroid dose Thoracic Society of Australia and New Zealand Annual Scientific Meeting; 2007 Mar 25-28; Auckland 2007 TP041"},{"issue":"(Suppl 29)","key":"10.1002\/14651858.CD011316.pub2-BIB0039|cit39","first-page":"19s","article-title":"Moderate to high dose inhaled corticosteroids in adult asthmatics: does salmeterol facilitate step down therapy? [Abstract]","volume":"12","author":"Rumbak","year":"1998","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD011316.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0011-393X(98)85106-0","article-title":"Does salmeterol facilitate 'step-down' therapy in patients with asthma receiving moderate to high doses of inhaled corticosteroids?","volume":"59","author":"Self","year":"1998","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"s4","key":"10.1002\/14651858.CD011316.pub2-BIB0041|cit41","first-page":"A141","article-title":"Step-down approach in chronic stable asthma; a comparison of reducing dose inhaled formoterol\/budesonide with maintaining inhaled budesonide [Abstract]","volume":"12","author":"Shamsul","year":"2007","journal-title":"Respirology"},{"issue":"2","key":"10.1002\/14651858.CD011316.pub2-BIB0042|cit42","first-page":"AB67","article-title":"ADRB2 (adrenergic B2 receptor agonist gene) Arg 16 allele and effect of LABA withdrawal in patients with moderate to severe asthma [Abstract]","volume":"127","author":"Slankard","year":"2011","journal-title":"Journal of Asthma and Clinical Immunology (Proceedings of the AAAAI Annual Meeting 2011)"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0043|cit43","first-page":"5","article-title":"Efficacy of budesonide\/formoterol (BUD\/FM) vs BUD in Hispanic patients: Differential results when including run-in lung function vs controller history and run-in symptoms [Abstract]","volume":"103","author":"Zangrilli","year":"2009","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0044|cit44","unstructured":"NCT01437995 Long-acting beta agonist step down study (LASST) Available from http:\/\/clinicaltrials.gov\/show\/NCT01437995"},{"issue":"1","key":"10.1002\/14651858.CD011316.pub2-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002738.pub2","article-title":"Beclomethasone versus placebo for chronic asthma","author":"Adams","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011316.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003135.pub4","article-title":"Fluticasone versus placebo for chronic asthma in adults and children","author":"Adams","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD011316.pub2-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011306","article-title":"Stopping long-acting beta2-agonists (LABA) for adults with asthma well-controlled on LABA and inhaled corticosteroids","author":"Ahmad","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/bmj.330.7499.1037","article-title":"Prevalence of asthma","volume":"330","author":"Anderson","year":"2005","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0049|cit49","unstructured":"National Asthma Council Australia Australian Asthma Handbook 2014, Version 1.0 www.asthmahandbook.org.au"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0165-6147(93)90184-L","article-title":"Anti-inflammatory actions of steroids: molecular mechanisms","volume":"14","author":"Barnes","year":"1993","journal-title":"Trends in Pharmacological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD011316.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1164\/ajrccm.164.5.9910103","article-title":"Inhaled corticosteroids, combined with long-acting beta2-agonists, improve the perception of bronchoconstriction in asthma","volume":"164","author":"Bijl-Hofland","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"23","key":"10.1002\/14651858.CD011316.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1056\/NEJM198312083092303","article-title":"Hypokalemia from beta2-receptor stimulation by circulating epinephrine","volume":"309","author":"Brown","year":"1983","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD011316.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/archinternmed.2012.3250","article-title":"Long-acting \u00df2-agonist step-off in patients with controlled asthma","volume":"172","author":"Brozek","year":"2012","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0054|cit54","unstructured":"British Thoracic Society Adult asthma audit report 2011 www.brit-thoracic.org.uk\/audit-and-quality-improvement\/"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0055|cit55","unstructured":"British Thoracic Society\/Scottish Intercollegiate Guidelines Network (BTS\/SIGN) British Guideline on the Management of Asthma http:\/\/www.brit-thoracic.org.uk\/guidelines\/asthma-guidelines.aspx"},{"issue":"8","key":"10.1002\/14651858.CD011316.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1513\/pats.200906-046DP","article-title":"Phenotypic differences between pediatric and adult asthma","volume":"6","author":"Bush","year":"2009","journal-title":"Proceedings of the American Thoracic Society"},{"issue":"4","key":"10.1002\/14651858.CD011316.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006923.pub3","article-title":"Regular treatment with formoterol for chronic asthma: serious adverse events","author":"Cates","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD011316.pub2-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010005.pub2","article-title":"Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews","author":"Cates","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011316.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010314.pub2","article-title":"Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews","author":"Cates","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8644","key":"10.1002\/14651858.CD011316.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(89)92505-1","article-title":"Prescribed fenoterol and death from asthma in New Zealand","volume":"1","author":"Crane","year":"1989","journal-title":"The Lancet"},{"issue":"5","key":"10.1002\/14651858.CD011316.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005535.pub2","article-title":"Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children","author":"Ducharme","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011316.pub2-BIB0062|cit62","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005533.pub2","article-title":"Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma","author":"Ducharme","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD011316.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"692","DOI":"10.7326\/0003-4819-145-9-200611070-00012","article-title":"Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids","volume":"146","author":"Ernst","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0064|cit64","unstructured":"United States Food Drug Administration FDA News Release: FDA Announces New Safety Controls for Long-Acting Beta Agonists, Medications Used to Treat Asthma http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm200931.htm"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0065|cit65","unstructured":"Global Initiative for Asthma Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger http:\/\/www.ginasthma.org\/Global-Strategy-for-the-Diagnosis-and-Management-of-Asthma-in-Children-5-Years-and-Younger"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0066|cit66","unstructured":"Global Initiative for Asthma (GINA) From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014 http:\/\/www.ginasthma.org\/local\/uploads\/files\/GINA_Report_2014_Jun11.pdf"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0067|cit67","unstructured":"International Union Against Tuberculosis and Lung Disease The Global Asthma Report 2011 Available from http:\/\/www.theunion.org\/what-we-do\/publications\/technical\/global-asthma-report"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1465-9921-15-83","article-title":"Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies","volume":"15","author":"Hern\u00e1ndez","year":"2014","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0069|cit69","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration www.cochrane-handbook.org"},{"issue":"9","key":"10.1002\/14651858.CD011316.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/thx.2009.119230","article-title":"Mechanisms of adverse effects of beta-agonists in asthma","volume":"64","author":"Johnston","year":"2009","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa1001278","article-title":"Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids","volume":"362","author":"Lemanske","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011316.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00002018-199716050-00002","article-title":"Airway subsensitivity with long-acting beta2-agonists: is there a cause for concern?","volume":"16","author":"Lipworth","year":"1997","journal-title":"Drug Safety"},{"issue":"5","key":"10.1002\/14651858.CD011316.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"e1147","DOI":"10.1542\/peds.2010-1720","article-title":"Age and risks of FDA-approved long-acting \u03b2\u2082-adrenergic receptor agonists","volume":"128","author":"McMahon","year":"2011","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0074|cit74","unstructured":"National Asthma Education and Prevention Program Guidelines for the Diagnosis and Management of Asthma www.nhlbi.nih.gov\/guidelines\/asthma\/asthgdln.pdf"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0075|cit75","unstructured":"NCT01462344 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (VESTRI) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01462344"},{"issue":"8","key":"10.1002\/14651858.CD011316.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJM199508243330807","article-title":"Beta-adrenergic bronchodilators","volume":"333","author":"Nelson","year":"1995","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1378\/chest.129.1.15","article-title":"The salmeterol multicenter asthma research trial","volume":"129","author":"Nelson","year":"2006","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD011316.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007949","article-title":"Addition of long-acting beta-agonists to inhaled corticosteroids for chronic asthma in children","author":"Ni Chroinin","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0079|cit79","unstructured":"Royal College of Physicians Why asthma still kills: the national review of asthma deaths https:\/\/www.rcplondon.ac.uk\/sites\/default\/files\/why-asthma-still-kills-full-report.pdf"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MCP.0b013e3282f1980b","article-title":"Safety of long-acting \u03b2-agonists in asthma: a review","volume":"14","author":"Oppenheimer","year":"2008","journal-title":"Current Opinion in Pulmonary Medicine"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0081|cit81","unstructured":"Public Health Agency of Canada Life and Breath: Respiratory Disease in Canada http:\/\/www.phac-aspc.gc.ca\/"},{"issue":"7","key":"10.1002\/14651858.CD011316.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009878.pub2","article-title":"Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth","author":"Pruteanu","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0083|cit83","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"904","DOI":"10.7326\/0003-4819-144-12-200606200-00126","article-title":"Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma related deaths","volume":"144","author":"Salpeter","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011316.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/j.1365-2222.2010.03541.x","article-title":"Phenotypes of childhood asthma: are they real?","volume":"40","author":"Spycher","year":"2010","journal-title":"Experimental Allergy"},{"issue":"2-3","key":"10.1002\/14651858.CD011316.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1385\/CRIAI:31:2:107","article-title":"Current issues with beta2-adrenoceptor agonists: historical background","volume":"31","author":"Tattersfield","year":"2006","journal-title":"Clinical Reviews in Allergy and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD011316.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1542\/peds.2010-1223","article-title":"Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review","volume":"127","author":"Zhang","year":"2011","journal-title":"Pediatrics"},{"issue":"7","key":"10.1002\/14651858.CD011316.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009471.pub2","article-title":"Inhaled corticosteroids in children with persistent asthma: effects on growth","author":"Zhang","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD011316.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T05:02:11Z","timestamp":1691816531000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011316.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,21]]},"references-count":88,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011316.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,21]]}}}